Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK
Biogen’s amyotrophic lateral sclerosis (ALS) treatment tofersen and Eli Lilly’s obesity drug tirzepatide made headway towards Japanese regulatory approval on December 2 by clearing the review of a key health ministry advisory panel. The two medicines, which are known as…
To read the full story
Related Article
- Qalsody, Zepbound, Zeposia Up for Advisory Panel Review on Dec. 2
November 19, 2024
- Biogen Files Tofersen as Japan’s 1st Genetic ALS Drug
May 22, 2024
- Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
May 9, 2024
- Argenx Seeks Label Expansion for Vyvdura in Japan
April 26, 2024
- Nippon Shinyaku Seeks Uptravi Use in Pediatric PAH in Japan
April 17, 2024
- Santen Seeks Japan Nod for Eye Drop Targeting Myopia
February 29, 2024
- BMS Files Ulcerative Colitis Med Ozanimod in Japan
February 27, 2024
- PeptiDream to Codevelop Lilly's Alzheimer’s Diagnostic Tauvid in Japan
November 25, 2022
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…